CC BY 4.0 · Pharmacopsychiatry 2022; 55(02): 95-107
DOI: 10.1055/a-1655-9500
Original Paper

Life-time Actionable Pharmacogenetic Drug Use: A Population-based Cohort Study in 86 040 Young People With and Without Mental Disorders in Denmark

Carin A.T.C. Lunenburg
1   Department of Affective Disorders, Aarhus University Hospital Psychiatry, Aarhus, Denmark
2   Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
,
Kazi Ishtiak-Ahmed
1   Department of Affective Disorders, Aarhus University Hospital Psychiatry, Aarhus, Denmark
2   Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
,
Thomas Werge
3   Institute of Biological Psychiatry, Mental Health Services, Copenhagen University Hospital, Copenhagen, Denmark
4   Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
5   Lundbeck Foundation Center for GeoGenetics, GLOBE Institute, University of Copenhagen, Copenhagen, Denmark
6   The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Copenhagen, Denmark
,
Christiane Gasse
1   Department of Affective Disorders, Aarhus University Hospital Psychiatry, Aarhus, Denmark
2   Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
7   Psychosis Research Unit, Aarhus University Hospital Psychiatry, Aarhus, Denmark
8   Centre for Integrated Register-based Research Aarhus University (CIRRAU), Aarhus, Denmark
› Institutsangaben

Abstract

Objective To describe life-time use of current actionable pharmacogenetic (PGx) somatic and psychotropic drugs according to international PGx consortia in people with and without hospital-diagnosed mental disorders in the Danish population.

Methods Population- and register-based observational drug utilization study in 56 065 individuals with mental disorders, i. e. attention-deficit/hyperactivity disorder, autism, bipolar disorder, depression and schizophrenia, and a random, representative sample of 29 975 individuals of the Danish population, born between 1981 and 2005. Individuals were followed from 1995 or birth until 2016 (for a maximum of 22 years). We report prevalence and incidence rates of PGx drug use by age, sex and mental disorders based on redeemed prescriptions between 1995 and 2016.

Results Of the 69 PGx drugs, prescriptions of 39 drugs had been redeemed by the study population by 35 years of age. The use of at least 1 PGx drug varied between 23.1% in males without mental disorders and 97.2% in females with schizophrenia. Males with ADHD or autism were the youngest first-time PGx drug users at a mean of 11.6 years. The mean number of different PGx drugs used was 1.2 in males without mental disorders and 5.6 in individuals with schizophrenia. The prevalence of different PGx drugs linked to more than one gene was 25.3% in males without mental disorders to 94.1% in females with schizophrenia.

Conclusion PGx drugs are commonly used by younger people, more often by individuals with mental disorders and by females. Panel-based PGx testing could contribute to treatment decisions at a very young age.

Supplementary Material



Publikationsverlauf

Eingereicht: 19. April 2021
Eingereicht: 31. August 2021

Angenommen: 08. September 2021

Artikel online veröffentlicht:
09. November 2021

© 2019. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany